Company News-宜明昂科英文

2025-11-27

ImmuneOnco's Amulirafusp Alfa (IMM0306) Phase III Clinical Trial Protocol Approved by CDE, Accelerating Development of Novel Therapy for Relapsed/Refractory Follicular Lymphoma

Amulirafusp Alfa (IMM0306), in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma (FL), has been formally approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA)

2025-10-31

Positive Progress of Amulirafusp Alfa (IMM0306) in the Treatment of Systemic Lupus Erythematosus (SLE) Presented at ACR Convergence 2025

On October 28, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco," with the stock code 01541.HK on the Hong Kong Stock Exchange) presented the latest results of the Phase

2025-10-02

Application for Phase III Clinical Trial of IMM2510 for IO-Resistant Non-Small Cell Lung Cancer Submitted to CDE

2025-09-17

Application for the Phase III Clinical Trial of IMM0306 for the Treatment of Follicular Lymphoma

2025-09-16

Important Milestone | IMM2510 (VEGF×PD-L1) Two Phase III Registration Clinical Trials Have Submitted EOP2 Innovative Therapy Enters Key Stage

IMM2510 has submitted End-of-Phase 2 (EOP2) communication applications for two Phase III registration clinical trials targeting different types of lung cancer to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).